MA38478A1 - Anticorps anti-pac1 humains - Google Patents

Anticorps anti-pac1 humains

Info

Publication number
MA38478A1
MA38478A1 MA38478A MA38478A MA38478A1 MA 38478 A1 MA38478 A1 MA 38478A1 MA 38478 A MA38478 A MA 38478A MA 38478 A MA38478 A MA 38478A MA 38478 A1 MA38478 A1 MA 38478A1
Authority
MA
Morocco
Prior art keywords
antibodies
pac1
antigen
binding fragments
human anti
Prior art date
Application number
MA38478A
Other languages
English (en)
Inventor
Cen Xu
Agnes Eva Hamburger
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA38478A1 publication Critical patent/MA38478A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des anticorps et des fragments de liaison à un antigène de ceux-ci qui se lient à pac1 humain. L'invention concerne des acides nucléiques codant pour les anticorps et des fragments de liaison à un antigène de ceux-ci, des vecteurs, et des cellules codant pour ceux-ci. Les anticorps et fragments de liaison à un antigène de ceux-ci peuvent inhiber la liaison de pac1 à pacap et sont utiles dans un nombre de troubles associés à pac1, comprenant le traitement et/ou la prévention de troubles de maux de tête, comprenant la migraine et l'algie vasculaire de la face.
MA38478A 2013-03-15 2014-03-14 Anticorps anti-pac1 humains MA38478A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792678P 2013-03-15 2013-03-15
PCT/US2014/029128 WO2014144632A2 (fr) 2013-03-15 2014-03-14 Anticorps anti-pac1 humains

Publications (1)

Publication Number Publication Date
MA38478A1 true MA38478A1 (fr) 2017-11-30

Family

ID=50439531

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38478A MA38478A1 (fr) 2013-03-15 2014-03-14 Anticorps anti-pac1 humains

Country Status (24)

Country Link
US (7) US9676851B2 (fr)
EP (2) EP3683237A1 (fr)
JP (3) JP6283408B2 (fr)
KR (1) KR102215405B1 (fr)
CN (1) CN105143267B (fr)
AP (1) AP2015008732A0 (fr)
AR (1) AR095611A1 (fr)
AU (2) AU2014228924B2 (fr)
CA (1) CA2906737C (fr)
CL (1) CL2015002750A1 (fr)
CR (1) CR20150575A (fr)
EA (1) EA032830B1 (fr)
ES (1) ES2770976T3 (fr)
HK (2) HK1219958A1 (fr)
IL (2) IL241382A0 (fr)
MA (1) MA38478A1 (fr)
MX (1) MX378292B (fr)
PE (1) PE20151923A1 (fr)
PH (1) PH12015502126A1 (fr)
SG (1) SG11201507416WA (fr)
TN (1) TN2015000425A1 (fr)
TW (2) TWI636064B (fr)
UY (1) UY35483A (fr)
WO (1) WO2014144632A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36302A (es) 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
CA2983030A1 (fr) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Utilisation d'anticorps anti-pacap et de leurs fragments de liaison a l'antigene pour le traitement, la prevention ou l'inhibition de la photophobie
TWI728953B (zh) 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
AR113022A1 (es) * 2017-09-29 2020-01-15 Lilly Co Eli Anticuerpo anti-pacap
KR102956517B1 (ko) 2017-10-04 2026-04-23 암젠 인크 트랜스타이레틴 면역글로불린 융합
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
CN111699003B (zh) * 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7339262B2 (ja) * 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
SG11202009629YA (en) 2018-04-02 2020-10-29 Amgen Inc Erenumab compositions and uses thereof
EP3774894A1 (fr) 2018-04-12 2021-02-17 Amgen Inc. Procédés de préparation de compositions protéiques stables
WO2020264384A1 (fr) 2019-06-28 2020-12-30 Amgen Inc. Protéines de liaison à l'antigène bispécifiques anti-récepteur pac1/anti-récepteur cgrp
CN118556079A (zh) 2021-07-29 2024-08-27 瑟法隆有限责任公司 抗pacap抗体的组合物和方法
CA3227990A1 (fr) * 2021-08-06 2023-02-09 Amgen Inc. Isolement de proteine therapeutique
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途
IL322653A (en) 2023-02-14 2025-10-01 H Lundbeck As Treating pain caused by opioids
WO2025226754A1 (fr) 2024-04-23 2025-10-30 Amgen Inc. Procédé de prédiction de l'osmolalité de solutions protéiques

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
CA2077764C (fr) 1990-03-17 2002-12-10 Nobuhiro Suzuki Anticorps contre la peptide activant l'adenylate-cyclase de l'hypophyse, et son utilisation
WO1991018982A1 (fr) 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
EP0593592B1 (fr) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
EP0618291A3 (fr) 1993-02-26 1997-12-03 Takeda Chemical Industries, Ltd. Protéine réceptrice-PACAP, méthode pour la préparation de cette protéine et l'utilisation de celle-ci
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CA2169298A1 (fr) 1993-09-10 1995-03-16 Martin Chalfie Utilisations d'une proteine fluorescente verte
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US6399316B1 (en) 1994-02-25 2002-06-04 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
US6462016B1 (en) 1995-10-06 2002-10-08 Shiseido Company, Ltd. Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
EP1972194A1 (fr) 1996-12-03 2008-09-24 Amgen Fremont Inc. Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
CA2196496A1 (fr) 1997-01-31 1998-07-31 Stephen William Watson Michnick Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
DE69941708D1 (de) 1998-07-20 2010-01-07 Ipsen Pharma Pacap-peptidanaloga
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
US20020155533A1 (en) 1998-11-30 2002-10-24 Takeda Chemical PACAP receptor protein, method for preparing said protein, and use thereof
US20020182729A1 (en) 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004046330A2 (fr) * 2002-11-15 2004-06-03 Morphotek, Inc. Methodes de generation d'une quantite elevee d'anticorps a partir d'hybridomes crees par immunisation in vitro
EP1583550A2 (fr) 2003-01-16 2005-10-12 D. Collen Research Foundation vzw Inhibition de la signalisation pacap dans la prevention et le traitement de la thrombocytopenie
US20050129687A1 (en) 2003-11-03 2005-06-16 University Of Vermont And State Agricultural College Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
JP2007522118A (ja) 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
WO2008018472A1 (fr) * 2006-08-08 2008-02-14 Kyoto University Nouvel anticorps monoclonal et son utilisation
WO2009003489A1 (fr) 2007-07-02 2009-01-08 Natimmune A/S POLYPEPTIDES DE LIAISON À L'ÉPITOPE CaOU-1
WO2009033489A2 (fr) 2007-09-11 2009-03-19 Glostrup Hospital Traitement de la migraine et de céphalées par des inhibiteurs sélectifs de pac1
CN101434649B (zh) 2008-12-12 2012-04-25 余榕捷 一种环七肽及其制备方法和应用
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
DK2459183T3 (en) 2009-07-27 2016-01-18 Nocicepta Llc Methods for the treatment of pain
WO2011035456A1 (fr) * 2009-09-25 2011-03-31 上海抗体药物国家工程研究中心有限公司 Procédé d'acquisition de protéines présentant une forte affinité au moyen d'une technique de conception assistée par ordinateur
KR20120107122A (ko) 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질
EP2554669B1 (fr) * 2010-03-26 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Nouvel anticorps ayant un site de modification introduit dans celui-ci, et fragment d'anticorps
WO2012125850A1 (fr) * 2011-03-16 2012-09-20 Amgen Inc. Variants de fc
CN102936303A (zh) * 2011-08-15 2013-02-20 沈阳欧陆科技发展有限公司 一种高氯含量的氯化聚氯乙烯树脂的合成方法
EP3539982B1 (fr) 2011-12-23 2025-02-19 Pfizer Inc. Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
WO2013177062A2 (fr) 2012-05-21 2013-11-28 Genentech, Inc. Procédés pour améliorer la sécurité du transport à travers la barrière hémato-encéphalique
WO2013180295A1 (fr) 2012-06-01 2013-12-05 日本電信電話株式会社 Procédé de traitement de transfert de paquets et dispositif de traitement de transfert de paquets
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
ES2770976T3 (es) 2020-07-06
JP2019024501A (ja) 2019-02-21
WO2014144632A2 (fr) 2014-09-18
AR095611A1 (es) 2015-10-28
WO2014144632A8 (fr) 2015-12-30
AU2019204980A1 (en) 2019-08-01
UY35483A (es) 2014-08-29
JP2018076373A (ja) 2018-05-17
US10793631B2 (en) 2020-10-06
US10053507B2 (en) 2018-08-21
US9822178B2 (en) 2017-11-21
BR112015023429A8 (pt) 2018-01-23
AU2014228924A1 (en) 2015-10-01
EA032830B1 (ru) 2019-07-31
US9676851B2 (en) 2017-06-13
PE20151923A1 (es) 2016-01-14
JP2016514458A (ja) 2016-05-23
US20150010560A1 (en) 2015-01-08
AU2014228924A9 (en) 2016-06-16
TN2015000425A1 (en) 2017-01-03
US20170247451A1 (en) 2017-08-31
TWI636064B (zh) 2018-09-21
IL262804A (en) 2018-12-31
US20180094055A1 (en) 2018-04-05
AU2014228924B2 (en) 2019-04-18
EP3683237A1 (fr) 2020-07-22
CN105143267A (zh) 2015-12-09
TW201522375A (zh) 2015-06-16
US20160251432A1 (en) 2016-09-01
KR102215405B1 (ko) 2021-02-10
US9365653B2 (en) 2016-06-14
EP2970470B1 (fr) 2019-12-04
CL2015002750A1 (es) 2016-03-04
WO2014144632A3 (fr) 2014-11-20
US20200172614A1 (en) 2020-06-04
JP6443870B2 (ja) 2018-12-26
PH12015502126A1 (en) 2016-01-25
MX2015013181A (es) 2015-12-11
CA2906737C (fr) 2023-08-15
JP6283408B2 (ja) 2018-02-21
CA2906737A1 (fr) 2014-09-18
US10472417B2 (en) 2019-11-12
AP2015008732A0 (en) 2015-09-30
US10294298B2 (en) 2019-05-21
CR20150575A (es) 2016-01-06
EA201591791A1 (ru) 2016-03-31
KR20150128982A (ko) 2015-11-18
HK1219958A1 (zh) 2017-04-21
MX378292B (es) 2025-03-10
CN105143267B (zh) 2020-06-26
HK1218554A1 (zh) 2017-02-24
US20180362645A1 (en) 2018-12-20
TW201902931A (zh) 2019-01-16
SG11201507416WA (en) 2015-10-29
EP2970470A2 (fr) 2016-01-20
US20160039939A1 (en) 2016-02-11
IL241382A0 (en) 2015-11-30
BR112015023429A2 (pt) 2017-11-28

Similar Documents

Publication Publication Date Title
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
MA38814B2 (fr) Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA64193B1 (fr) Anticorps bispécifiques se liant aux dll3 et cd3
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
EA201591791A1 (ru) Антитела pac1 человека
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA39096B1 (fr) Anticorps spécifiques à fcrn
MA38930A1 (fr) Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)
MA39342B2 (fr) Anticorps il -21
NZ626242A (en) Anti-asic1 antibodies and uses thereof
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA38485A1 (fr) Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe
WO2019032945A9 (fr) Agent liant cd40 et utilisations associées
PH12014501985A1 (en) Il-17 antibody formulation
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
MA39336A1 (fr) Molécules d'anticorps anti-lag-3 et leurs utilisations
MA56083B1 (fr) Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient
MA39221B1 (fr) Molécules d'anticorps anti-tim-3 et leurs utilisations
MA35863B1 (fr) Anticorps anti-asic1 et leurs utilisations